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Epidemiology and pathophysiology of obesity as cause of cancer
Abstract
According to World Health Organisation estimates 1.1 billion people were overweight or obese
worldwide in the year 2000 with the prevalence rapidly increasing. Compelling evidence suggests that
excess body weight is a risk factor for several cancer types including cancer of the colon, breast,
endometrium, kidney, oesophagus, as well as possibly additional sites. According to previous
meta-analyses and systematic literature reviews, an important proportion of cancer has been estimated to
be attributable to excess body weight. The extrapolation of a European meta-analysis [1] to the Swiss
situation broadly estimates that around 700 cancers could be prevented in the absence of overweight and
obesity in this country. The data presented highlights the public health relevance of preventing excess
body weight. Several interacting metabolic and hormonal pathways seem to underlie the association
between being overweight and cancer with insulin-resistance playing a central role. Since evidence is
mounting that excess body weight can also adversely affect cancer prognosis, obesity is a primary target
for cancer control programs.
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According to World Health Organisation es-
timates 1.1 billion people were overweight or
obese worldwide in the year 2000 with the preva-
lence rapidly increasing. Compelling evidence
suggests that excess body weight is a risk factor for
several cancer types including cancer of the colon,
breast, endometrium, kidney, oesophagus, as well
as possibly additional sites. According to previous
meta-analyses and systematic literature reviews, an
important proportion of cancer has been estimated
to be attributable to excess body weight. The ex-
trapolation of a European meta-analysis [1] to the
Swiss situation broadly estimates that around 700
cancers could be prevented in the absence of over-
weight and obesity in this country. The data pre-
sented highlights the public health relevance of
preventing excess body weight. Several interacting
metabolic and hormonal pathways seem to under-
lie the association between being overweight and
cancer with insulin-resistance playing a central
role. Since evidence is mounting that excess body
weight can also adversely affect cancer prognosis,
obesity is a primary target for cancer control pro-
grams.
Key words: obesity; cancer; overweight
The prevalence of excess weight and obesity is
rapidly increasing worldwide. Convincing evi-
dence relates being overweight to the risk for sev-
eral types of cancer as well as other chronic ill-
nesses, including cardiovascular disease, stroke
and diabetes [2] which are responsible for a large
percentage of premature mortality [3]. The Inter-
national Agency for Research on Cancer reviewed
the literature on the association between excess
body weight and cancer risk. They judged the
available evidence as sufficient for a causal link
with cancers of the colon, female breast (post-
menopausal), endometrium, kidney (renal cell),
and oesophagus (adenocarcinoma). Preliminary
evidence also exists to suggest a relationship with
additional cancer sites [4].
This report gives an overview on the epidemi-
ological and biological evidence regarding the as-
sociation between excess weight/obesity and can-
cer. The specific aim of this publication is to dis-
cuss the relevance of obesity for cancer burden and
control based on data from several existing and
thorough systematic literature reviews and formal
meta-analyses. 
Summary
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Abbreviations
BMI body mass index
FFAs free fatty acids
IGF-1 insulin-like growth factor
IGFBP-1/-2 insulin-like growth factor binding proteins 1 and 2
IL-6 interleukin-6
PAR% population attributable risk
SHBG sex hormone binding globulin
TNFa tumour necrosis factor a
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The World Health Organisation (WHO) de-
fines obesity as “an abnormal or excessive fat accu-
mulation in adipose tissue, to the extent that health
is impaired” [5]. The currently accepted classifica-
tion of obesity for epidemiological purposes de-
fines overweight at body mass index (BMI) levels
greater than 25 kg/m2 and obesity beginning at
BMI of 30 kg/m2 [5]. But different cut-off points
have been used to define overweight and obesity 
in some previous studies. For example some 
Canadian studies defined overweight as a BMI 
>27 kg/m2 [6, 7].
Lifestyle changes with associated increased
high fat/energy-rich foods and reduced physical
activity have led to a rapid increase in excess weight
and obesity worldwide. Worldwide 1.1 billion peo-
ple are currently estimated to be overweight, at
least 300 million of them obese [5]. Between 1992
and 2002 the percentage of the Swiss population
that was overweight increased from 25% to 29%;
the percentage that was obese increased from 5.5%
to 8% [40] The obesity epidemic observed in chil-
dren is of special concern [8, 9].
Overweight and obesity: definition and prevalence
Overweight and cancer: summary of the epidemiological evidence
Worldwide, cancer represents a major health
problem with roughly 22 million persons living
with cancer in the year 2000 [10]. Currently, obe-
sity follows cigarette consumption in public health
relevance as a cause of avoidable cancer in West-
ern society. Bergström et al. [1] estimated that in
the European Union excess body weight accounts
for 5% of all incident cancers, 3.5% in men and
6.5% in women. This corresponds to additional
27 000 male and 45 000 female cancer cases each
year. In addition to increasing the likelihood of de-
veloping cancer, obesity has also been associated
with cancer mortality. In the largest prospective
study to date [11] excess body weight accounted for
14% of all deaths from cancer in men and 20% of
those in women, respectively.
Breast cancer
Weight gain during adult life has consistently
been associated with breast cancer risk. The rela-
tionship varies according to the menopausal status.
While overweight seems to produce a protective
effect in premenopausal women, it is consistently
associated with an increased breast cancer risk after
menopause [12, 13], especially among those who
have never used of hormone replacement therapy
[14]. The relevance of obesity as prognostic factor
in breast cancer patients has not been conclusively
elucidated. Available information suggests an in-
dependent association of overweight with higher
risk of tumour recurrence and poorer overall sur-
vival in both, pre- and postmenopausal women 
[12, 15, 16]. Overall, the strength of this relation-
ship seems to be modest. More recent evidence
suggests that excess body weight adversely affects
outcome especially in specific subpopulations of
breast cancer patients, as reported for pre- or per-
imenopausal women [17], for women who have
never smoked [18], and for women with oestrogen
receptor-negative breast cancers or breast cancers
diagnosed at early stages [19].
Endometrial cancer
The association between overweight (BMI
>25 kg/m2) and endometrial cancer has been
demonstrated consistently in several studies and
estimates ranged between a 2- and 5-fold risk in-
crease (reviewed in: [4, 20]). Contrary to breast
cancer, the effect of obesity on endometrial cancer
risk seems to remain constant throughout adult life
independent of menopausal status. Although over-
weight and obesity were consistently related to in-
creased endometrial cancer risk, the few analyses
reporting results on their relevance as prognostic
factor are contradictory [4, 11].
Colorectal cancer
Studies reviewed by the International Agency
for Research on Cancer [4] indicated an associa-
tion between excess body weight and/or abdomi-
nal fat and risk for colorectal cancer. Relative risk
estimates ranged from 1.2 to 2.0. Obesity may
influence the development of colorectal cancer at
an early stage in tumorigenesis as suggested by 
studies showing an association between BMI and
incidence as well as recurrence of adenomatous
polyps, precursor lesions of colorectal cancer
[21–25].
A gender difference has been described with
an increased risk for colon cancer in men but not
consistently in women [20, 26, 27]. Reasons for this
gender difference are not known, but several hy-
potheses have been reported. A stronger relation-
ship between central adiposity, more common 
in men, and colon cancer risk has been proposed
[20]. Alternatively, oestrogen produced in greater
amount by obese postmenopausal women may
exert a protective effect leading to a diminished
obesity-related risk in women [4]. However, a 
recent analysis [28] found the increased colon can-
cer risk to be restricted to obese women who were
“oestrogen positive” (premenopausal women or
women using hormone replacement therapy). The
authors hypothesised that oestrogen up-regulates
the insulin like growth factor system in the colon
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thereby increasing susceptibility to obesity-in-
duced insulin.
There is also evidence for an interaction be-
tween excess weight/obesity and physical activity,
which is a strong protective factor against colon
cancer. Slattery et al. [29] reported the greatest risk
of development of colon cancer among men with
large BMI if they were in the least physically 
active group and in the group with the highest 
energy intake suggesting that energy balance as a
whole seems to be associated with risk of colon
cancer. The role of excess body weight as a prog-
nostic factor for colorectal cancer is inconclusive.
Calle et al. [11] found a statistically significant
positive linear trend of mortality with increasing
BMI in men and less strongly in women.
Renal-cell cancer
Epidemiological studies consistently reported
an increased risk of renal cell carcinoma among in-
dividuals, especially women, with high BMI inde-
pendent of other risk factors such as hypertension
and diabetes (reviewed in: [1, 4, 20, 30]). 
Calle et al. [11] found an increased mortality
rate in overweight men and women with a dose-
effect relationship. Patients with renal cell carci-
noma have a more favourable prognosis if they are
obese, both in terms of recurrence-free and over-
all survival [31–33]. These results await confirma-
tion by large scale analyses.
Oesophageal cancer
In Western countries the incidence of oeso-
phageal adenocarcinoma, but not of squamous-cell
carcinoma has been rapidly increasing during the
last decades [4]. Only a limited number of studies
have analysed the relationship between excess
body weight and oesophageal carcinoma, but have
consistently shown a 2–3-fold increased risk of
adenocarcinoma of the oesophagus and to a lower
extent of the gastric cardia with increasing BMI
[20, 30]. The relationship of obesity with a higher
incidence of gastro-oesophageal reflux has been
proposed as putative causal mechanism [4].
Calle et al. [11] reported a linear increase of
death rates with higher BMI in men. The same
trend was found in women, however without
reaching statistical significance.
Prostate cancer
The International Agency for Research on
Cancer summarised available data on the relation-
ship between obesity and prostate cancer from a
large number of studies as controversial and not
suggesting any association [4]. These contrasting
results may reflect a complex relationship between
excess weight and prostate cancer which can differ
in subpopulations of cancer patients. For example,
the association seems to vary by cancer aggressive-
ness [34, 35] and patients’ age at diagnosis [36, 37].
Obesity may play a more important role in prostate
cancer progression as opposed to aetiology [11, 38,
39].
Gallbladder cancer
Only a limited number of small studies
analysed the effect of being overweight on the risk
of gallbladder cancer. According to Calle et al. 
[20] cancer risk increases two-fold in overweight
subjects. Because of the small study populations
available the IARC-working group defined the
data currently available as inconclusive [4].
Excess weight has been related to higher
mortality rates of gallbladder cancer in both men
and women, the latter showing a stronger relation-
ship [11].
Others
Some studies reported enhanced cancer risks
related to excess body weight for several additional
cancer sites, including pancreatic, ovarian- and
cervical cancer and cancers of the haematopoietic
system. The available evidence in this respect is too
limited to be conclusive [4, 20, 30].
Excess weight and cancer: attributable risk
Table 1 shows the estimates of the proportion
of cancers attributable to excess weight and obe-
sity as reported by Bergström et al. [1] for Europe.
We extrapolated these estimates of the attributa-
ble cancer fraction to the Swiss population by using
National Health Survey data on the overweight
and obesity prevalence in the Swiss population
[40]. The meta-analysis by Bergström et al. [1] was
based on the systematic analysis of the epide-
miological literature for six cancer sites (colon-,
postmenopausal breast-, endometrium-, renal-,
prostate- and gallbladder-cancer) and estimated
summary relative risks. We did not consider
prostate- and gallbladder-cancers for the extrapo-
lation to the Swiss situation because at present 
this sites lack strong evidence for a casual link be-
tween excess weight/obesity and cancer develop-
ment. 
Overall, due to the higher obesity prevalence,
Europe presents a higher proportion of attributa-
ble cancer cases than Switzerland. According to
these estimates the greatest proportion of cancers
attributable to excess body weight is expected for
endometrium and renal cancers. Due to their low
incidence however, they account for only a small
number of additional cancer cases. The largest
number of attributable cases is expected for colon
cancer. From a gender-specific perspective the
largest absolute impact of obesity is expected for
postmenopausal breast cancer in women and for
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colon cancer in men. Overall, Bergström et al. [1]
estimated that 4.2% of all cancers could be avoided
in the EU population. This amounts to 2.0% in the
Swiss population, corresponding to additional 700
cancer cases. Several aspects must be considered in
the interpretation of this estimate. First, the esti-
mation of the excess number of cancer cases in the
Swiss population could be underestimated because
data on the prevalence of obesity is based on self
reporting in the National Health Survey. Second,
the assumption of a causal relationship between ex-
cess body weight and cancer underlies the calcula-
tion of the attributable disease fraction. As out-
lined above the International Agency for Research
on Cancer judged the available evidence as suffi-
cient for a causal link with cancers of the colon,
female breast (postmenopausal), endometrium,
kidney (renal cell), and oesophagus (adenocarci-
noma); preliminary evidence also suggests a rela-
tionship with additional cancer sites [4]. As we
considered only cancer sites for which strong evi-
dence for a causal relationship with excess weight
is available, the above estimates may be a conser-
vative approximation of the true attributable
numbers. Third, confounding of the obesity-can-
cer associations may have lead to an overestima-
tion of the attributable fractions. Whenever possi-
ble Bergström et al. [1] restricted the inclusion of
studies for their meta-analysis to the ones account-
ing for major confounders of the obesity-cancer
associaton at each site. However, to avoid a major
loss of information, some summary RRs used for
the estimation of the attributable fractions were
derived from studies not accounting for major con-
founders. Therefore, we cannot rule out a certain
proportion of the estimated excess risk as being
due to residual or unmeasured confounding rather
than a true causal impact of excess weight/obesity
on cancer development [41].
Cancer site RR RR PAF% PAF% Nr. of cases 
for overweight1 vs. for obese2 vs. in EU in CH in CH
normal weight [1] normal weight [1] population [1] population population
Cancer incidence
Colon men 1.15 1.33 11.1 7.6 157
Colon women 1.15 1.33 10.7 5.5 101
Breast in post- 1.12 1.25 8.5 6.2 172
menopausal women3
Endometrium 1.59 2.52 39.2 19.5 160
Renal cell 1.36 1.84 25.0 15.6 101
Total cancers 4.2 2.0 691
1 Overweight, 25 ≤BMI <30
2 Obese, BMI ≥30 RR = Relative Risk (source for RR estimate ranges: [1]) 
3 Women ≥55 yrs only. PAF% in EU derived from [1].
The population attributable fraction (PAR%) for the Swiss population was calculated using the following equation [71]: 
PAR% = PF1 {RR1-1} + PF2{RR2-1} / 1 + PF1 (RR1-1) + PF2 (RR2-1) PF1 denotes the proportion of the total population 
in the overweight category, and PF2 the proportionof people who are considered as obese. 
Prevalence estimates for overweight and obesity in the Swiss population are derived from the latest Swiss National Health Survey [72]. 
Specific risk estimates describing the association between overweight / obesity and cancer risk in the Swiss population (RR1 and RR2) 
are not available. Subsequently, in order to estimate the impact of excess body weight on cancer burden in Switzerland, we used relative
risk estimates for the most relevant cancer sites reported in a recent extensive review [1]. Number of cases in CH estimated relating
PAF% with the total number of new cancer cases reported by the Association Swiss Cancer Registries (www.vskr.ch).
Table 1
Population attributa-
ble fractions (PAF%)
according to excess
body weight in Eu-
rope and Switzerland
(incl. number of can-
cer cases) for overall
and site-specific can-
cer incidence, based
on a meta-analysis
by Bergström et al.
[1].
Excess weight and cancer: pathophysiological mechanisms
Mechanisms by which excess weight/obesity
induce carcinogenesis and their respective rele-
vance are likely to vary by cancer site. At present
the biological mechanisms which link excess
weight/obesity and cancer are well understood
only for cancer types with an endocrine compo-
nent such as breast- or endometrium cancer. These
and other, less understood biological pathways
proposed in the literature, are briefly discussed
below.
The adipose tissue, known for its primary
function as energy storage organ, has been more
recently identified as an important endocrine
organ reacting to different signals and secreting a
wide range of factors (ie, adipokines). Some of
these mediators, perturbed in obesity, have been
linked to obesity-related morbidity known as
“metabolic syndrome” [42–44]. A major molecu-
lar consequence of obesity and principal patho-
physiological feature of the metabolic syndrome is
the insulin-resistance, a metabolic state in which
muscle and liver tissues present a reduced response
capacity to insulin (fig. 1).
Nutritional insulin resistance associated with
obesity may be a reflection of the lipotoxic effects
of fatty acids as well as of an adipokine imbalance,
two pathways interacting in a vicious circle. The
elevated basal lipolysis and the consecutively in-
creased plasma concentrations of free fatty acids
(FFAs) accounts for their increased intracellular
accumulation which can impair nonadipose cells in
their normal function and insulin signaling. This
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phenomenon is referred to as “lipotoxicity” [45].
Lipotoxicity is additionally associated with an al-
tered secretory profile of adipokines. For example
the impaired function of leptin, adiponectin and
resistin (which have a major role in the control of
food intake and energy expenditure) by obesity has
been correlated with a decreased insulin sensitiv-
ity [45]. Furthermore, in the insulin-resistant state
pro-inflammatory mediators such as tumour
necrosis factor-a (TNFa) and interleukin-6 (IL-
6) are upreglated in adipose tissue [45]. TNFa can
exacerbate the insulin resistance through a direct
paracrine inactivation of the insulin receptor as well
as through elevation of circulating FFAs level [46].
Hyperinsulinaemia / Insulin-like 
growth factor-I
Insulin resistance is correlated to a subsequent
compensatory overproduction of pancreatic in-
sulin. Chronic hyperinsulinaemia has been linked
to carcinogenesis and related to colon [47, 73],
endometrium [49], pancreas [47, 50] and breast
cancers [47, 48]. Both, the direct impact of insulin
on target cells and the indirect effect through
secondary metabolic and endocrine changes can
underlie its carcinogenic effect. Insulin enhances
the Insulin-like growth factor (IGF-1) synthesis
and its bioavailability. The insulin-induced de-
creased production of the insulin-like growth fac-
tor binding proteins-1 and -2 (IGFBPs-1 and -2)
results in the subsequent rise of plasma levels of
free IGF-I. Both, insulin and IGF-I are anabolic
molecules that can promote tumour development
by inhibiting apoptosis, and by stimulating cell
proliferation [47, 51, 52]. High concentrations of
IGF-I have been related to an increased risk of
prostate and premenopausal breast cancer [51, 53]. 
Endogenous sex steroids
Obesity has been associated with lower levels
of sex hormone-binding globulin (SHBG) and
plasma total and bioavailable androgens and
oestrogens. Sex steroids are mitogens that can
stimulate cell proliferation, inhibit apoptosis, and
therefore potentially increase the chance of
malignant cell transformation, particularly of en-
dometrium and breast [49, 54, 55] but possibly also
at other organ sites (eg, prostate- [56], colorectal
cancer [57]. Several mechanisms may link obesity
with the level of sex steroids. First, insulin and
IGF-I stimulate the synthesis of sex steroids in
ovarian, testicular or adrenal tissue, and inhibit the
hepatic synthesis of SHBG, increasing their free
circulating levels and bioavailability to tissues [47,
52]. The increased production of androgen from
the ovarian thecal cells and possibly from the ad-
renal gland [58] leads to anovulatory cycles and
lower progesterone levels. This syndrom, named
polycystic ovary syndrom (PCOS), is a metabolic
disorder also associated with insulin resistance. 
It has been related to a higher risk for endo-
metrial cancer [49]. Finally, adipocytes express sex
hormone metabolising enzymes and are the main
site of oestrogen production in postmenopausal
women. Obese women show higher aromatisation
of androgenic precursors to oestrogens with BMI
positively correlated with circulating sex-hormone
levels [55, 59].
Inflammation and oxidative stress
Obesity is related to a condition of chronic in-
flammation characterised by abnormal production
of inflammatory cytokines with local (eg, TNFa)
or systemic effects (eg, IL-6) that can contribute to
the development of malignant disease [45, 46, 60].
Chronic inflammation induced by obesity can
affect both tumour initiation and tumour progres-
sion. Iyengar et al. [61] described for example that
Figure 1
Mechanisms linking
excess weight to in-
creased cancer risk.
17b-HSD, 17b-hy-
droxysteroid dehy-
drogenase; T, Testos-
teron; A, Androsten-
dion; E1, oestrone;
E2, oestradiol; FFAs,
free fatty acids; TNFa,
tumour necrosis fac-
tor a; IL-6, interleu-
kin-6; SHBG, sex-hor-
mon-binding globu-
lin; IGFBP 1 / 2, in-
sulin-like growth fac-
tor binding protein 
1 / 2; IGF I, insulin-
like growth factor I.
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adipocyte-conditioned medium can promote tu-
morigenesis in breast cancer cells, including cell
proliferation, invasive potential, angiogenesis and
the induction of the cross-talk between cancer cells
and the surrounding extracellular matrix [62–65].
1863, Rudolf Virchow suggested a connection
between inflammation and cancer after the obser-
vation of lymphoreticular infiltrate in neoplastic
tissues [62]. In recent years, improved understand-
ing of the inflammatory microenvironment of
malignant tissues has supported this hypothesis.
Over-expression of TNFa and IL-6, as well as
other cytokines is common in malignant and/or
stromal cells in several malignancies such as breast,
prostate, colorectal, and ovarian cancer [62].
Animal models produced direct evidence for the
carcinogenic potential of these cytokines. For ex-
ample mice lacking the gene for TNFa are resist-
ant to skin cancer development [66]. Several mo-
lecular mechanisms have been proposed to explain
the carcinogenic effects of chronic inflammation
and inflammatory markers. First, reactive oxygen
species (ROS) are often generated by inflamma-
tory cells and cytokines in order to destroy patho-
genic agents in the acute defence reaction. How-
ever, as demonstrated in vivo and in vitro [67, 68],
obesity causes a chronic overproduction of ROS
which can induce mutagenic changes and may
damage DNA repair proteins contributing to
cancer development [69]. Second, pro-inflamma-
tory adipokines can improve insulin resistance as
discussed above. 
The process relating obesity to cancer devel-
opment is multifactorial and involves a network of
metabolic and immunological factors. The differ-
ential role of the biological mechanisms in various
cancer sites has to be defined and mechanisms
related to the imbalance of adipokines by obesity
need to be further elucidated in future research. In
addition, the interaction of body weight (as well as
of additional indicators for excess weight, ie, waist-
hip-ratio) with lifestyle, environmental and ge-
netic factors in determining cancer incidence,
survival and mortality must be investigated in the
different cultural contexts. These investigations
would permit to identify susceptible target groups
in various populations for future obesity inter-
ventions. 
Conclusion
The excess weight epidemic represents a big
challenge for national health care systems [70].
The cancer-related estimates presented in this re-
port further highlight the public health relevance
of preventing excess weight. They stress the fact
that obesity must be a central aspect of cancer re-
search and cancer control. 
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